Literature DB >> 24189054

PDE2 inhibition: potential for the treatment of cognitive disorders.

Laurent Gomez1, J Guy Breitenbucher.   

Abstract

Phosphodiesterase inhibition has received much attention in the past 20 years for the potential treatment of CNS disorders. A primary focus of this work is the enhancement of memory and/or cognitive functioning. The role of PDEs in the augmentation of cyclic nucleotide signaling makes these enzymes attractive targets for enhancing the effects of neuronal communication. This review focuses on recent findings with respect to the role of PDE2 inhibition in cognitive functioning. Special attention is paid to recently disclosed, selective tool compounds and the use of these tool compounds to support the role of PDE2 inhibition in cognition. Recently reported SAR and modeling work will be presented along with discussion of the entry of new PDE2 inhibitors into the clinic.
Copyright © 2013 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Cognition; Drug discovery; Memory; Phosphodiesterase

Mesh:

Substances:

Year:  2013        PMID: 24189054     DOI: 10.1016/j.bmcl.2013.10.014

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  16 in total

1.  The neuroprotective and antidepressant-like effects of Hcyb1, a novel selective PDE2 inhibitor.

Authors:  Li Liu; Jing Zheng; Xian-Feng Huang; Xia Zhu; Shu-Ming Ding; Heng-Ming Ke; James M O'Donnell; Han-Ting Zhang; Guo-Qiang Song; Ying Xu
Journal:  CNS Neurosci Ther       Date:  2018-04-27       Impact factor: 5.243

2.  First-in-Human Assessment of the Novel PDE2A PET Radiotracer 18F-PF-05270430.

Authors:  Mika Naganawa; Rikki N Waterhouse; Nabeel Nabulsi; Shu-Fei Lin; David Labaree; Jim Ropchan; Sanela Tarabar; Nicholas DeMartinis; Adam Ogden; Anindita Banerjee; Yiyun Huang; Richard E Carson
Journal:  J Nucl Med       Date:  2016-04-21       Impact factor: 10.057

3.  Potential Treatment of Cognitive Impairment in Schizophrenia by Phosphodiesterase 2 (PDE2) Inhibitors.

Authors:  Ahmed F Abdel-Magid
Journal:  ACS Med Chem Lett       Date:  2016-12-29       Impact factor: 4.345

4.  Pyrido[4,3-e][1,2,4]triazolo[4,3-a]pyrazines as Selective, Brain Penetrant Phosphodiesterase 2 (PDE2) Inhibitors.

Authors:  Frederik J R Rombouts; Gary Tresadern; Peter Buijnsters; Xavier Langlois; Fulgencio Tovar; Thomas B Steinbrecher; Greet Vanhoof; Marijke Somers; José-Ignacio Andrés; Andrés A Trabanco
Journal:  ACS Med Chem Lett       Date:  2015-01-15       Impact factor: 4.345

5.  Selective phosphodiesterase-2A inhibitor alleviates radicular inflammation and mechanical allodynia in non-compressive lumbar disc herniation rats.

Authors:  Jun-Nan Wang; Xue-Jun Zhao; Zhi-Hua Liu; Xu-Li Zhao; Tao Sun; Zhi-Jian Fu
Journal:  Eur Spine J       Date:  2017-03-10       Impact factor: 3.134

6.  Structure-Guided Design and Procognitive Assessment of a Potent and Selective Phosphodiesterase 2A Inhibitor.

Authors:  Shawn J Stachel; Richard Berger; Ashley B Nomland; Anthony T Ginnetti; Daniel V Paone; Deping Wang; Vanita Puri; Henry Lange; Jason Drott; Jun Lu; Jacob Marcus; Michael P Dwyer; Sokreine Suon; Jason M Uslaner; Sean M Smith
Journal:  ACS Med Chem Lett       Date:  2018-07-26       Impact factor: 4.345

7.  Assay of Calcium Transients and Synapses in Rat Hippocampal Neurons by Kinetic Image Cytometry and High-Content Analysis: An In Vitro Model System for Postchemotherapy Cognitive Impairment.

Authors:  Patrick M McDonough; Natalie L Prigozhina; Ranor C B Basa; Jeffrey H Price
Journal:  Assay Drug Dev Technol       Date:  2017-07       Impact factor: 1.738

Review 8.  Phosphodiesterase type 5 and cancers: progress and challenges.

Authors:  Ines Barone; Cinzia Giordano; Daniela Bonofiglio; Sebastiano Andò; Stefania Catalano
Journal:  Oncotarget       Date:  2017-10-12

9.  Investigation of an 18F-labelled Imidazopyridotriazine for Molecular Imaging of Cyclic Nucleotide Phosphodiesterase 2A.

Authors:  Susann Schröder; Barbara Wenzel; Winnie Deuther-Conrad; Rodrigo Teodoro; Mathias Kranz; Matthias Scheunemann; Ute Egerland; Norbert Höfgen; Detlef Briel; Jörg Steinbach; Peter Brust
Journal:  Molecules       Date:  2018-03-02       Impact factor: 4.411

10.  HITS-CLIP in various brain areas reveals new targets and new modalities of RNA binding by fragile X mental retardation protein.

Authors:  Thomas Maurin; Kevin Lebrigand; Sara Castagnola; Agnès Paquet; Marielle Jarjat; Alexandra Popa; Mauro Grossi; Florence Rage; Barbara Bardoni
Journal:  Nucleic Acids Res       Date:  2018-07-06       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.